Apr 12 minRS Oncology to present translational data identifying potential biomarkers associated with RSO-021 anticancer activity.RS Oncology will present translational research data at the AACR annual meeting 4/7 & 4/9
Mar 46 minRecent advancements in treating malignant pleural mesothelioma, and why localized treatment could be advantageousGeorge Naumov, COO at RS Oncology, summarizes a few of the recent advancements in malignant pleural mesothelioma treatment and discusses...
Feb 12 minRS Oncology Announces First Patient Dosed in Phase 2 Clinical Study (MITOPE) Investigating RSO-021 for the Treatment of Malignant Pleural Mesothelioma and Metastatic Disease to the LungCambridge, MA, USA and Leicester, UK, February 1, 2024 -- RS Oncology (RSO), a clinical stage biotechnology company developing...
Nov 15, 20233 minTop 10 Questions to Ask Your Doctor About Your Malignant Mesothelioma Cancer DiagnosisMalignant Mesothelioma can be confusing and devastating. Pronouncing “Mesothelioma” is a challenge, as is the disease. You are your best...